STOCKHOLM, Aug. 31, 2021 /PRNewswire/ -- During August, the
number of shares and votes in Calliditas Therapeutics AB (publ) has
increased due to the directed share issue of 2,400,000 new shares
that the company carried out on August 12,
2021. Thus, as of August 31,
2021, the number of shares and votes in the company amounts
to 52,341,584.
For further information, please contact:
Mikael Widell, Investor
relations
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com
The information in the press release is such that Calliditas
Therapeutics AB (publ) is required to disclose pursuant to the
Swedish Financial Instruments Trading Act. The information was
submitted for publication, through the agency of the contact
persons set out above, at 8:00 CEST
on August 31, 2021.
About Calliditas
Calliditas Therapeutics is a biopharma company based in
Stockholm, Sweden focused on
identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product candidate, Nefecon, is a proprietary, novel oral
formulation of budesonide, an established, highly potent local
immunosuppressant, for the treatment of adults with the autoimmune
renal disease primary IgA nephropathy (IgAN), for which there is a
high unmet medical need and there are no approved treatments.
Calliditas has recently read out topline data from Part A of its
global Phase 3 study in IgAN and, if approved, aims to
commercialize Nefecon in the United
States. Calliditas is also planning to start clinical trials
with NOX inhibitors in primary biliary cholangitis and head and
neck cancer. Calliditas is listed on Nasdaq Stockholm (ticker:
CALTX) and the Nasdaq Global Select Market (ticker: CALT).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/number-of-shares-and-votes-in-calliditas-therapeutics,c3402934
The following files are available for download:
https://mb.cision.com/Main/16574/3402934/1458807.pdf
|
Calliditas_-_Pressmeddelande_-_Antalet_aktier_och_röster_(eng)
|